Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion Buys Out Portola, But Analysts Don’t See Value

Executive Summary

The acquisition brings Alexion the bleeding reversal agent Andexxa, which execs called a synergistic addition to its portfolio – but analysts are struggling to see the match with Alexion’s chronic rare disease therapies.

You may also be interested in...



Alexion Buys A Complementary Business With Achillion

The company agreed to pay $930m up front to acquire Achillion, which has two drugs in Phase II development for complement alternative pathway-mediated rare diseases.

Portola Finally Gets FDA OK For Factor Xa Antidote AndexXa

It has taken a while and there were concerns that another trial may be needed before approval but AndexXa has got the green light in the US as a reversal agent for Eliquis and Xarelto. It comes with a warning and post-marketing commitments but Portola has very high hopes.

Kura May Have Found A Place For Tipifarnib In Head-And-Neck Cancer

The repurposed drug showed substantial improvement over existing therapies in second-line treatment of patients with HRAS-mutant tumors.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142222

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel